Biofrontera (NASDAQ:BFRIW – Get Free Report) is projected to post its results after the market closes on Friday, August 7th. Analysts expect the company to announce earnings of ($0.1050) per share and revenue of $9.50 million for the quarter.
Biofrontera Price Performance
BFRIW opened at $0.03 on Wednesday. The business’s 50-day moving average price is $0.03 and its two-hundred day moving average price is $0.04. Biofrontera has a 1 year low of $0.02 and a 1 year high of $0.19.
Biofrontera Company Profile
Biofrontera AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.
The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device.
Featured Stories
- Five stocks we like better than Biofrontera
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
